Addex Therapeutics Ltd (SWX:ADXN)

Market Cap	6.53M
Revenue (ttm)	158.54K
Net Income (ttm)	-6.10M
Shares Out	116.57M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,080
Average Volume	215,165
Open	0.0560
Previous Close	0.0558
Day's Range	0.0552 - 0.0560
52-Week Range	0.0472 - 0.0850
Beta	2.10
RSI	49.52
Earnings Date	Apr 6, 2026

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ADXN